| TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells S Mariathasan, SJ Turley, D Nickles, A Castiglioni, K Yuen, Y Wang, ... Nature 554 (7693), 544-548, 2018 | 4221 | 2018 |
| Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm … JE Rosenberg, J Hoffman-Censits, T Powles, MS Van Der Heijden, ... The Lancet 387 (10031), 1909-1920, 2016 | 3892 | 2016 |
| Tumor mutational load predicts survival after immunotherapy across multiple cancer types RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ... Nature genetics 51 (2), 202-206, 2019 | 3460 | 2019 |
| Comprehensive molecular characterization of urothelial bladder carcinoma Cancer Genome Atlas Research Network Nature 507 (7492), 315, 2014 | 2757 | 2014 |
| Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial AV Balar, MD Galsky, JE Rosenberg, T Powles, DP Petrylak, J Bellmunt, ... The Lancet 389 (10064), 67-76, 2017 | 2253 | 2017 |
| Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206 BI Rini, S Halabi, JE Rosenberg, WM Stadler, DA Vaena, SS Ou, L Archer, ... Journal of Clinical Oncology 26 (33), 5422-5428, 2008 | 1182 | 2008 |
| Pneumonitis in patients treated with anti–programmed death-1/programmed death ligand 1 therapy J Naidoo, X Wang, KM Woo, T Iyriboz, D Halpenny, J Cunningham, ... Journal of Clinical Oncology 35 (7), 709-717, 2017 | 1151 | 2017 |
| Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206 BI Rini, S Halabi, JE Rosenberg, WM Stadler, DA Vaena, L Archer, ... Journal of clinical oncology 28 (13), 2137-2143, 2010 | 1080 | 2010 |
| Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline SS Chang, BH Bochner, R Chou, R Dreicer, AM Kamat, SP Lerner, ... The Journal of urology 198 (3), 552-559, 2017 | 970 | 2017 |
| Enfortumab vedotin in previously treated advanced urothelial carcinoma T Powles, JE Rosenberg, GP Sonpavde, Y Loriot, I Durán, JL Lee, ... New England Journal of Medicine 384 (12), 1125-1135, 2021 | 854 | 2021 |
| Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial P Sharma, MK Callahan, P Bono, J Kim, P Spiliopoulou, E Calvo, ... The lancet oncology 17 (11), 1590-1598, 2016 | 766 | 2016 |
| Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy MD Galsky, NM Hahn, J Rosenberg, G Sonpavde, T Hutson, WK Oh, ... Journal of clinical oncology 29 (17), 2432-2438, 2011 | 673 | 2011 |
| Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma EM Van Allen, KW Mouw, P Kim, G Iyer, N Wagle, H Al-Ahmadie, C Zhu, ... Cancer discovery 4 (10), 1140-1153, 2014 | 631 | 2014 |
| Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy JE Rosenberg, PH O’Donnell, AV Balar, BA McGregor, EI Heath, EY Yu, ... Journal of Clinical Oncology 37 (29), 2592-2600, 2019 | 588 | 2019 |
| Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior … CJ Ryan, MR Smith, L Fong, JE Rosenberg, P Kantoff, F Raynaud, ... Journal of clinical oncology 28 (9), 1481-1488, 2010 | 510 | 2010 |
| Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma TK Choueiri, U Vaishampayan, JE Rosenberg, TF Logan, AL Harzstark, ... Journal of Clinical Oncology 31 (2), 181-186, 2013 | 507 | 2013 |
| Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma BI Rini, MD Michaelson, JE Rosenberg, RM Bukowski, JA Sosman, ... Journal of Clinical Oncology 26 (22), 3743-3748, 2008 | 495 | 2008 |
| Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens J Bellmunt, TK Choueiri, R Fougeray, FAB Schutz, Y Salhi, E Winquist, ... Journal of Clinical Oncology 28 (11), 1850-1855, 2010 | 480 | 2010 |
| Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers MY Teo, K Seier, I Ostrovnaya, AM Regazzi, BE Kania, MM Moran, ... Journal of Clinical Oncology 36 (17), 1685-1694, 2018 | 478 | 2018 |
| Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials TK Choueiri, FAB Schutz, Y Je, JE Rosenberg, J Bellmunt Journal of Clinical Oncology 28 (13), 2280-2285, 2010 | 462 | 2010 |
Hikmat Al-AhmadieMemorial Sloan Kettering Cancer Center在 mskcc.org 的电子邮件经过验证
